Despite a drop-off in deal numbers, 2019 was a great year for biopharma IP owners
Last year’s M&A and licensing figures suggest that there is a sellers' market in many types of life sciences assets
To read more
Register for limited access
Register to receive our newsletter and gain limited access to subscriber content.
Register now
Subscribe and start reading now
Subscribe for unlimited access to articles, in-depth analysis and research from the IAM experts.
Subscribe now